NovoCure Limited - Ordinary Shares (NVCR): Price and Financial Metrics

NovoCure Limited - Ordinary Shares (NVCR)

Today's Latest Price: $167.55 USD

11.39 (-6.37%)

Updated Jan 15 4:00pm

Add NVCR to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

NVCR Stock Summary

  • NVCR's current price/earnings ratio is 951.16, which is higher than 98.86% of US stocks with positive earnings.
  • Price to trailing twelve month operating cash flow for NVCR is currently 346.11, higher than 98.82% of US stocks with positive operating cash flow.
  • Over the past twelve months, NVCR has reported earnings growth of -2,119.91%, putting it ahead of merely 1.03% of US stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to NovoCure Ltd are NUAN, GORO, KTOS, CELH, and PGNY.
  • To check out NovoCure Ltd's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001645113.

NVCR Stock Price Chart Interactive Chart >

Price chart for NVCR

NVCR Price/Volume Stats

Current price $167.55 52-week high $182.74
Prev. close $178.94 52-week low $53.40
Day low $167.41 Volume 923,200
Day high $179.69 Avg. volume 750,530
50-day MA $148.80 Dividend yield N/A
200-day MA $98.20 Market Cap 17.06B

NovoCure Limited - Ordinary Shares (NVCR) Company Bio

NovoCure Limited is a commercial stage oncology company which develops treatment for solid tumor cancers therapy called the tumor treating fields. The company was founded in 2000 and is based in Saint Helier, Channel Islands.

NVCR Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$167.55$7493.63 4088%

Below please find a table outlining a discounted cash flow forecast for NVCR, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that NovoCure Ltd ranked in the 95th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 4108.5% on a DCF basis. As for the metrics that stood out in our discounted cash flow analysis of NovoCure Ltd, consider:

  • The compound growth rate in the free cash flow of NovoCure Ltd over the past 1.5 years is 3.93%; that's better than 95.1% of cash flow producing equities in the Healthcare sector, where it is classified.
  • The business' balance sheet reveals debt to be 0% of the company's capital (with equity being the remaining amount). Approximately only 2.24% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • NovoCure Ltd's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than merely 0% of US stocks with positive free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of NovoCure Ltd? See MNKKQ, CYH, AMEH, RDY, and BEAT.

NVCR Latest News Stream

Event/Time News Detail
Loading, please wait...

NVCR Latest Social Stream

Loading social stream, please wait...

View Full NVCR Social Stream

Latest NVCR News From Around the Web

Below are the latest news stories about NovoCure Ltd that investors may wish to consider to help them evaluate NVCR as an investment opportunity.

Are Options Traders Betting on a Big Move in NovoCure (NVCR) Stock?

Investors need to pay close attention to NovoCure (NVCR) stock based on the movements in the options market lately.

Yahoo | January 15, 2021

Novocure Announces Fourth Quarter and Full Year 2020 Preliminary Net Revenues and Provides Company Update

ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure reported operating statistics and preliminary, unaudited net revenues and cash balances for the fourth quarter and full year 2020.

Business Wire | January 11, 2021

Novocure Could Weaken Further in the Days Ahead

NovoCure Stock Could Weaken Further in the Days Ahead…NVCR

The Street RealMoney | January 4, 2021

NovoCure Could Weaken Further in the Days Ahead

NovoCure Ltd. is pulling back Monday and the weakness may not be over. In early November we reviewed the charts of NVCR and wrote that, "If you are still long NVCR from early October then I would continue to hold those positions but raise stop protection to a close below $110 now." In the updated daily Japanese candlestick chart of NVCR, below, we can see some upper shadows last month telling us that traders were rejecting the highs.

Yahoo | January 4, 2021

Insider Selling: NovoCure Limited (NASDAQ:NVCR) CEO Sells 207,910 Shares of Stock

NovoCure Limited (NASDAQ:NVCR) CEO Asaf Danziger sold 207,910 shares of NovoCure stock in a transaction dated Friday, December 18th. The shares were sold at an average price of $157.39, for a total value of $32,722,954.90. Following the transaction, the chief executive officer now directly owns 301,587 shares in the company, valued at approximately $47,466,777.93. The […]

Watchlist News | December 25, 2020

Read More 'NVCR' Stories Here

NVCR Price Returns

1-mo 4.59%
3-mo 26.61%
6-mo 164.02%
1-year 80.98%
3-year 709.42%
5-year 882.12%
YTD -3.17%
2020 105.34%
2019 151.70%
2018 65.74%
2017 157.32%
2016 -64.89%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8488 seconds.